How can altering DNA help defeat one of the world’s deadliest diseases? This video explores how scientists are using CRISPR ...

Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...

Dr. Tobias Bexte will share recent advances that overcome key barriers to making NK cell therapies safe, effective and widely ...

Prof. Lukas Dow, biochemistry, and his team published a study in Nature on Aug. 16, detailing a new, more specific gene editing tool that they created to study cancer mutations through preclinical ...

Cancer cells are known to reawaken embryonic genes to grow. A new study reveals the disease also hijacks the proteins, or "editors", that control how those genes are read.

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

A one-time gene-editing therapy, exagamglogene autotemcel (exa-cel), has demonstrated sustained and clinically meaningful ...

A glucose-sensitive nanovaccine delivers CRISPR to tumors, silences immune-suppressing genes, and activates a targeted immune response against cancer. (Nanowerk Spotlight) Immune-based cancer ...

Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer. Researchers from Tel Aviv University (Israel), led by Razan Masarwy, have investigated utilizing CRISPR ...

In a significant turn of events, Intellia Therapeutics has announced the temporary suspension of dosing and patient screening in two late-stage studies of its groundbreaking gene-editing treatment ...